Skip to main content

Table 4 Subgroup analysis of the association between K-ras mutations and overall survival of patients with pancreatic cancer

From: Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

Subgroup

No. of patients with mutant K-ras

No. of patients without mutant K-ras

HR (95 % CI)

Heterogeneity I 2 (%)

Heterogeneity P value

Ethnicity

 Caucasian

650

234

1.35 (1.10–1.63)

28.0

0.195

 Asian

586

327

1.65 (1.32–1.72)

0.0

0.136

Publication year

 Before 2010

309

127

1.27 (0.96–1.69)

33.1

0.175

 After 2010

927

434

1.58 (1.36–1.83)

0.0

0.963

Tumor resectability

 Resectable

594

301

1.44 (1.19–1.74)

14.3

0.315

 Unresectable

586

241

1.57 (1.30–1.91)

0.0

0.686

Treatment

 Operation

451

208

1.35 (1.09–1.69)

35.7

0.183

 Chemotherapy

586

241

1.57 (1.30–1.91)

0.0

0.686

 Operation + chemotherapy

143

93

1.71 (1.18–2.48)

0.0

0.574

Detection methods

 Sequencing

428

235

1.57 (1.29–1.90)

0.0

0.644

 Other methods

808

326

1.46 (1.22–1.75)

2.0

0.421